Search Results

The American Diabetes Association® and The Leapfrog Group announced the first hospitals to receive national designation as Recognized Leaders in Caring for People Living with Diabetes.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa) today announced its sponsorship of the American Heart Association’s new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis.

Senseonics Holdings, Inc. announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL.

Altimmune, Inc. today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that results from the prevalence phase of its CATALYST study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented at the American Diabetes Association’s 84th Scientific Sessions.

The American Diabetes Association ® announced the winners of its Innovation Challenge competition. Innovators showcased novel ideas for diabetes care before a panel of potential funders and an audience of professionals in the field, with the goal of furthering transformative solutions for people living with diabetes, their families, and caregivers.

Veru Inc. announced that the Company will present two presentations at the American Diabetes Association’s 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

Altimmune, Inc., a clinical-stage biopharmaceutical company, presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis, on cardioinflammatory lipids at the American Diabetes Association’s 84th Scientific Sessions.

MAIA Biotechnology, Inc. announced that Dr. Rachid Drissi, Principal Investigator at the Center for Childhood Cancer Research, Nationwide Children’s Hospital, and Associate Professor at Ohio State University, will present an abstract detailing the potency of THIO, MAIA’s telomere-targeting agent, as treatment for pediatric brain cancers at the American Association for Cancer Research Annual Meeting taking place April 5–10, 2024 in San Diego, California.